Published in J Immunol on March 01, 1976
Suppression of macrophage oxidative metabolism by products of malignant and nonmalignant cells. J Exp Med (1982) 1.58
Macrophages and resistance to tumours. I. Inhibition of delayed-type hypersensitivity reactions by tumour cells and by soluble prducts affecting macrophages. Immunology (1978) 1.37
Effect of virus infection on the inflammatory response. Depression of macrophage accumulation in influenza-infected mice. Am J Pathol (1976) 1.16
Effect of tetracycline treatment on immunological responses in mice. Clin Exp Immunol (1980) 1.13
Alterations of mononuclear phagocyte function induced by Lewis lung carcinoma in C57BL mice. Br J Cancer (1977) 1.10
Tumour-associated inhibition of immediate hypersensitivity reactions in mice. Immunology (1977) 1.06
Macrophage migratory dysfunction in cancer. A mechanism for subversion of surveillance. Am J Pathol (1977) 1.05
Resistance of neoplasms to immunological destruction: role of a macrophage chemotaxis inhibitor. J Exp Med (1978) 1.02
The tumoricidal properties of inflammatory tissue macrophages and multinucleate giant cells. Am J Pathol (1979) 0.99
Impaired chemotactic responsiveness of macrophages from gnotobiotic rats. Infect Immun (1978) 0.97
Subversion of host defense mechanisms by malignant tumors: an established tumor as a privileged site for bacterial growth. J Exp Med (1977) 0.97
Down-modulation of monocyte transendothelial migration and endothelial adhesion molecule expression by fibroblast growth factor: reversal by the anti-angiogenic agent SU6668. Am J Pathol (2002) 0.93
Inhibition by the Landschütz ascites carcinoma of the granulomatous inflammatory response to C. parvum. Br J Cancer (1982) 0.88
Effects of the Landschütz ascites carcinoma and ascitic fluid on macrophage activity in C. parvum-injected mice. Br J Cancer (1981) 0.84
Different patterns of macrophage infiltration into allogeneic-murine and xenogeneic-human neoplasms growing in nude mice. Am J Pathol (1992) 0.83
Anti-inflammation induced by counter-irritation or by treatment with non-steroidal agents inhibits the growth of a tumour of non-detected immunogenicity. Br J Cancer (1989) 0.81
Impaired resistance to bacterial infection after tumor implant is traced to lactic dehydrogenase virus. Infect Immun (1980) 0.80
Alveolar macrophage dysfunction in malignant lung tumours. Thorax (1984) 0.80
Piroxicam, indomethacin and aspirin action on a murine fibrosarcoma. Effects on tumour-associated and peritoneal macrophages. Clin Exp Immunol (1991) 0.79
Immunosuppressive retroviral-related factors in sera of patients with head and neck cancer. Eur Arch Otorhinolaryngol (1990) 0.78
Tumour related inhibition of macrophage chemotaxis in patients with colon cancer. Gut (1987) 0.75
The induction of human peripheral blood lymphoid colonies by conditioned media from human tumour cell lines. Immunology (1980) 0.75
Serum biochemical changes in c. parvum-injected mice bearing the Landschütz ascites carcinoma. Br J Exp Pathol (1982) 0.75
Effect of pregnancy of cellular inflammation. Br J Exp Pathol (1982) 0.75
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer (1977) 53.23
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer (1976) 22.55
Conservatism of the approximation sigma (O-E)2-E in the logrank test for survival data or tumor incidence data. Biometrics (1973) 18.14
A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. Am J Epidemiol (2000) 13.17
Specific receptor sites for chemotactic peptides on human polymorphonuclear leukocytes. Proc Natl Acad Sci U S A (1977) 5.87
Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer (2002) 5.83
Migration patterns and breast cancer risk in Asian-American women. J Natl Cancer Inst (1993) 5.07
Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst (2000) 4.93
Calibration of the dietary questionnaire for a multiethnic cohort in Hawaii and Los Angeles. Am J Epidemiol (2000) 4.46
Breast cancer in young women and use of oral contraceptives: possible modifying effect of formulation and age at use. Lancet (1983) 4.38
Human mononuclear leukocyte chemotaxis: a quantitative assay for humoral and cellular chemotactic factors. J Immunol (1972) 4.38
Chemotactic and anaphylatoxic fragment cleaved from the fifth component of guinea pig complement. Science (1968) 3.69
Estrogens and endometrial cancer in a retirement community. N Engl J Med (1976) 3.64
'Hormonal' risk factors, 'breast tissue age' and the age-incidence of breast cancer. Nature (1983) 3.63
Undescended testis: the effect of treatment on subsequent risk of subfertility and malignancy. J Pediatr Surg (1986) 3.54
Apparent doubling of frequency of undescended testis in England and Wales in 1962-81. Lancet (1984) 3.54
Risk factors for cancer of the testis in young men. Int J Cancer (1979) 3.42
Increased cell division as a cause of human cancer. Cancer Res (1990) 3.38
Meta-analysis: dietary fat intake, serum estrogen levels, and the risk of breast cancer. J Natl Cancer Inst (1999) 3.35
Interactions of the complement system with endotoxic lipopolysaccharide. Generation of a factor chemotactic for polymorphonuclear leukocytes. J Exp Med (1968) 3.33
Treatment of zoster with idoxuridine in dimethyl sulphoxide. Results of two double-blind controlled trials. Br Med J (1970) 3.30
Endogenous hormones as a major factor in human cancer. Cancer Res (1982) 3.30
Inhibition of lymphocyte proliferation by a synthetic peptide homologous to retroviral envelope proteins. Science (1985) 3.27
New Concepts Regarding Anterior Drainage of the Eye. Br J Ophthalmol (1950) 3.24
rac, a novel ras-related family of proteins that are botulinum toxin substrates. J Biol Chem (1989) 3.21
Familial testicular cancer: a report of the UK family register, estimation of risk and an HLA class 1 sib-pair analysis. Br J Cancer (1992) 3.10
The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer (1988) 3.07
The chemotactic attraction of human fibroblasts to a lymphocyte-derived factor. J Exp Med (1976) 3.04
Trends in mortality among British doctors in relation to their smoking habits. J R Coll Physicians Lond (1972) 2.99
Statistical analysis of patient-control studies in epidemiology. Factor under investigation an all-or-none variable. Br J Prev Soc Med (1970) 2.94
The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol (1988) 2.91
Oral contraceptive use and early abortion as risk factors for breast cancer in young women. Br J Cancer (1981) 2.89
A method of analysis of a certain class of experiments in carcinogenesis. Biometrics (1966) 2.86
Reaction of a cobra venom factor with guinea pig complement and generation of an activity chemotactic for polymorphonuclear leukocytes. Proc Soc Exp Biol Med (1969) 2.76
Dengue fever epidemics in the South Pacific: driven by El Niño Southern Oscillation? Lancet (1996) 2.72
Risk of testicular cancer in cohort of boys with cryptorchidism. BMJ (1997) 2.71
A case of refractory schistosomiasis. Med J Aust (1996) 2.69
El Niño and the dynamics of vectorborne disease transmission. Environ Health Perspect (1999) 2.62
A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. Nat Rev Cancer (2005) 2.62
Identification of beta-adrenergic receptors in human lymphocytes by (-) (3H) alprenolol binding. J Clin Invest (1976) 2.58
Antibodies to human papillomavirus and to other genital infectious agents and invasive cervical cancer risk. Lancet (1993) 2.58
The influence of climate variation and change on diarrheal disease in the Pacific Islands. Environ Health Perspect (2001) 2.54
Cancer incidence in the Mexican-American. J Natl Cancer Inst (1975) 2.54
A neutrophil chemotatic factor derived from C'5 upon interaction of guinea pig serum with endotoxin. J Immunol (1969) 2.54
A potential second messenger role for unsaturated fatty acids: activation of Ca2+-dependent protein kinase. Science (1984) 2.53
Neisseria meningitidis and Neisseria gonorrhoeae bacteremia associated with C6, C7, or C8 deficiency. Ann Intern Med (1979) 2.51
Geographical variation in mortality from leukaemia and other cancers in England and Wales in relation to proximity to nuclear installations, 1969-78. Br J Cancer (1989) 2.50
The long-term prognosis of severe infantile malnutrition. Lancet (1967) 2.44
Burkitt's tumour in the West Nile District Uganda, 1961-5. Br Med J (1967) 2.43
Toward the primary prevention of cancer. Science (1991) 2.41
Calcium influx requirement for human neutrophil chemotaxis: inhibition by lanthanum chloride. Science (1976) 2.34
Estrogen exposure during gestation and risk of testicular cancer. J Natl Cancer Inst (1983) 2.34
An improved approximate formula for calculating sample sizes for comparing two binomial distributions. Biometrics (1978) 2.32
An inherited abnormality of neutrophil adhesion. Its genetic transmission and its association with a missing protein. N Engl J Med (1980) 2.32
Epidemiology of soy exposures and breast cancer risk. Br J Cancer (2008) 2.22
A human mononuclear leukocyte chemotactic factor: characterization, specificity and kinetics of production by homologous leukocytes. J Immunol (1973) 2.18
"Incessant ovulation" and ovarian cancer. Lancet (1979) 2.18
A chemotactic factor for mononuclear leukocytes. Proc Soc Exp Biol Med (1971) 2.18
Significance of complement to the mechanism of action of endotoxin. Curr Top Microbiol Immunol (1969) 2.18
Biological activity of complement in vivo. Role of C5 in the accumulation of polymorphonuclear leukocytes in inflammatory exudates. J Exp Med (1971) 2.15
An epidemiologic study of breast cancer. J Natl Cancer Inst (1974) 2.15
Depression of macrophage function by a factor produced by neoplasms: a merchanism for abrogation of immune surveillance. J Immunol (1976) 2.11
Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. Br Med J (Clin Res Ed) (1986) 2.08
Molecular and cellular mechanisms of leukocyte chemotaxis. Science (1981) 2.07
Disease clustering: a generalization of Knox's approach to the detection of space-time interactions. Biometrics (1968) 2.06
Stroke prevention and oestrogen replacement therapy. Lancet (1989) 2.05
The question of estrogen replacement therapy in patients with a prior diagnosis of breast cancer. Oncology (Williston Park) (1990) 2.04
Chemoattractant receptor-induced hydrolysis of phosphatidylinositol 4,5-bisphosphate in human polymorphonuclear leukocyte membranes. Requirement for a guanine nucleotide regulatory protein. J Biol Chem (1985) 2.03
A controlled trial of the treatment of Mycobacterium ulcerans infection with clofazimine. Lancet (1973) 2.02
Chemoattractant receptors on phagocytic cells. Annu Rev Immunol (1984) 2.01
Human copper-zinc superoxide dismutase transgenic mice are highly resistant to reperfusion injury after focal cerebral ischemia. Stroke (1994) 1.99
Guidelines for simple, sensitive significance tests for carcinogenic effects in long-term animal experiments. IARC Monogr Eval Carcinog Risk Chem Hum Suppl (1980) 1.99
Regulation of human chemokine receptors CXCR4. Role of phosphorylation in desensitization and internalization. J Biol Chem (1997) 1.98
Pilot clinical trial of gabapentin to decrease postoperative delirium in older patients. Neurology (2006) 1.97
The relationship between breast cancer and augmentation mammaplasty: an epidemiologic study. Plast Reconstr Surg (1986) 1.90
Activation of complement by endotoxin: a role for 2 globulin, C1, C4 and C2 in the consumption of terminal complement components by endotoxin-coated erythrocytes. J Immunol (1972) 1.90
Requirement of S-adenosyl-L-methionine-mediated methylation for human monocyte chemotaxis. Proc Natl Acad Sci U S A (1978) 1.89
Four dimensions of fear of dental injections. J Am Dent Assoc (1997) 1.88
A conserved region at the COOH terminus of human immunodeficiency virus gp120 envelope protein contains an immunodominant epitope. Proc Natl Acad Sci U S A (1987) 1.87
Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk. J Natl Cancer Inst (1994) 1.87
Normal perfusion pressure breakthrough theory. Clin Neurosurg (1978) 1.87
Slow mortality rate accelerations during aging in some animals approximate that of humans. Science (1990) 1.86
Urinary 2-hydroxyestrone/16alpha-hydroxyestrone ratio and risk of breast cancer in postmenopausal women. J Natl Cancer Inst (1999) 1.85
Long survivals in acute leukaemia. Lancet (1973) 1.85
Decreased properdin activity in acute glomerulonephritis. Int Arch Allergy Appl Immunol (1969) 1.83
Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res (1993) 1.82
Potential role for a guanine nucleotide regulatory protein in chemoattractant receptor mediated polyphosphoinositide metabolism, Ca++ mobilization and cellular responses by leukocytes. Biochem Biophys Res Commun (1985) 1.82
Human immunodeficiency virus-related lymphoma. Prognostic factors predictive of survival. Cancer (1991) 1.81
Receptor-coupled activation of phosphoinositide-specific phospholipase C by an N protein. Science (1986) 1.81
Biologic and biochemical activities of continuous macrophage cell lines P388D1 and J774.1. J Immunol (1977) 1.81
Effect of age at orchidopexy on risk of testicular cancer. Lancet (1986) 1.80
An inhibitor of macrophage chemotaxis produced by neoplasms. Science (1976) 1.79
5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet (1992) 1.77